These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 29412121)

  • 1. Sodium-glucose Cotransporter 2 Inhibitors: Impact on Body Weight and Blood Pressure Compared with other Antidiabetic Drugs.
    Imprialos KP; Stavropoulos K; Stavropoulos N; Patoulias D; Petidis K; Grassos C; Dimitriadis K; Tsioufis C
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):104-113. PubMed ID: 29412121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease.
    Stavropoulos K; Imprialos KP; Stavropoulos N; Bouloukou S; Kerpiniotis G; Dimitriadis K; Tsioufis C; Doumas M
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):120-126. PubMed ID: 29412122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose Cotransporter 2 Inhibitors: Potential Cardiovascular and Mortality Benefits.
    Lovic D; Pittaras A; Kallistratos M; Tsioufis C; Grassos C; Djordjevic D; Tasic I; Manolis A
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):114-119. PubMed ID: 29485012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose Cotransporter 2 Inhibitors: The Impact on Development and Progression of Heart Failure.
    Papademetriou V; Geladari E
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):127-133. PubMed ID: 29618313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes.
    Kramer CK; Zinman B
    Annu Rev Med; 2019 Jan; 70():323-334. PubMed ID: 30256723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature.
    Imprialos K; Faselis C; Boutari C; Stavropoulos K; Athyros V; Karagiannis A; Doumas M
    Curr Pharm Des; 2017; 23(10):1510-1521. PubMed ID: 28120716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose Cotransporter 2 Inhibitors: The Pleiotropic Mechanisms of Actions.
    Pantelidis P; Kalliakmanis A; Mitas C; Sideris M; Grassos C; Pittaras A; Manolis A
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):86-93. PubMed ID: 29412123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose Cotransporter 2 Inhibitors: Glucose Lowering Against other Hypoglycemic Agents.
    Avranas K; Imprialos K; Stavropoulos K; Lales G; Manafis A; Skalkou A; Kihm L
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):94-103. PubMed ID: 29412124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?
    Imprialos KP; Sarafidis PA; Karagiannis AI
    J Hypertens; 2015 Nov; 33(11):2185-97. PubMed ID: 26372321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment.
    Weir MR
    Postgrad Med; 2019 Aug; 131(6):367-375. PubMed ID: 31132013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose Cotransporter 2 Inhibitors and Ischemic Stroke.
    Milonas D; Tziomalos K
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):134-138. PubMed ID: 29412119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives.
    Maccari R; Ottanà R
    J Med Chem; 2022 Aug; 65(16):10848-10881. PubMed ID: 35924548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium Glucose Co-Transporter 2 Inhibitors: Beyond Glucose Lowering.
    Ceylan AF; Ren SY
    Curr Drug Targets; 2018; 19(9):1045-1050. PubMed ID: 29673309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence.
    Yabiku K
    Front Endocrinol (Lausanne); 2021; 12():768850. PubMed ID: 34950104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):633-647. PubMed ID: 28393583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors.
    Cersosimo E; Miles JM
    Curr Diabetes Rev; 2019; 15(4):314-327. PubMed ID: 30101716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis; from Pathophysiology to Clinical Practice.
    Patoulias D; Manafis A; Mitas C; Avranas K; Lales G; Zografou I; Sambanis C; Karagiannis A
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):139-146. PubMed ID: 29412120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
    Schwartz SS; Ahmed I
    Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The mechanisms and clinical potential: sodium-glucose cotransporter 2 (SGLT-2) inhibitors treating diabetic kidney disease].
    Wang YJ; Hao CM
    Sheng Li Xue Bao; 2018 Dec; 70(6):663-669. PubMed ID: 30560277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus.
    Guthrie RM
    Postgrad Med; 2013 May; 125(3):21-32. PubMed ID: 23748504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.